Pirfenidone modifies hepatic miRNAs expression in a model of MAFLD/NASH

Pirfenidone modifies hepatic miRNAs expression in a model of MAFLD/NASH

Abstract miRNAs are involved in the development of metabolic associated fatty liver disease (MAFLD) and nonalcoholic steatohepatitis (NASH). We aimed to evaluate modifications by prolonged-release pirfenidone (PR-PFD) on key hepatic miRNAs expression in a MAFLD/NASH model. First, male C57BL/6J mice...

Full description

Bibliographic Details
Main Authors: Rebeca Escutia-Gutiérrez, J. Samael Rodríguez-Sanabria, C. Alejandra Monraz-Méndez, Jesús García-Bañuelos, Arturo Santos-García, Ana Sandoval-Rodríguez, Juan Armendáriz-Borunda
Format: Article
Language:English
Published: Nature Publishing Group 2021-06-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-021-91187-2

Internet

https://doi.org/10.1038/s41598-021-91187-2

Similar Items